FLXN Flexion Therapeutics Inc.

13.35
-0.32  -2%
Previous Close 13.67
Open 13.53
Price To Book 3.46
Market Cap 505387439
Shares 37,856,737
Volume 525,513
Short Ratio
Av. Daily Volume 736,812

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166323
  2. 8-K - Current report 181166183
  3. CT ORDER - Confidential treatment order 181108419
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18997989
  5. 8-K - Current report 18997884

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 4Q 2018.
Zilretta - SHIP
Osteoarthritis of the Shoulder and Hip
Approval announced October 6, 2017.
Zilretta - FX006
Osteoarthritis of the knee
Phase 2 top-line data released November 2016.
Zilretta - FX006
Osteoarthritis of the knee with type 2 adult diabetes
sNDA planned for 4Q 2018.
Zilretta - FX006 repeat
Osteoarthritis of the knee
Top-line safety data due 2Q 2018.
Zilretta - FX006
Osteoarthritis of the knee

Latest News

  1. Here's Why Flexion Therapeutics Jumped 20.5% in November
  2. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  3. 2 Small Biotech Stocks That Insiders Are Buying
  4. Flexion Therapeutics Inc (NASDAQ:FLXN): What Does Its Beta Value Mean For Your Portfolio?
  5. New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
  6. Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe 
  7. Edited Transcript of FLXN earnings conference call or presentation 7-Nov-18 9:30pm GMT
  8. Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates
  9. Flexion Therapeutics: 3Q Earnings Snapshot
  10. Flexion Therapeutics Reports Third-Quarter 2018 Financial Results and Recent Business Highlights
  11. Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019
  12. Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018
  13. Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting
  14. Factors of Influence in 2018, Key Indicators and Opportunity within Iamgold, Mazor Robotics, Flexion Therapeutics, Hemisphere Media Group, Criteo S.A, and EP Energy — New Research Emphasizes Economic Growth

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166323
  2. 8-K - Current report 181166183
  3. CT ORDER - Confidential treatment order 181108419
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18997989
  5. 8-K - Current report 18997884
  6. 8-K - Current report 18911920
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18814476
  8. 8-K - Current report 18814433
  9. 8-K - Current report 18809741
  10. 8-K - Current report 18806123